Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 03:03:16 28/05/2024 BST			5-day change	1st Jan Change
7.86 ^HKD	+0.26%		-14.29%	-78.04%

05-20	Sirnaomics' Strategy Chief Steps Down	MT
05-17	Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer	CI

Sirnaomics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023

August 30, 2023 at 11:38 pm

Sirnaomics Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was USD 37.96 million compared to USD 41.88 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.55 a year ago.

Latest news about Sirnaomics Ltd.

Sirnaomics' Strategy Chief Steps Down	05-20	MT
Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer	05-17	CI
Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	05-10	CI
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	04-17	MT
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ	04-16	CI
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Sirnaomics Chairman Disposes of Shares	03-08	MT
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug	12-18	MT
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study	12-06	MT
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	12-05	CI
Sirnaomics Ltd. Announces Executive Changes	11-30	CI
Sirnaomics Shows Positive Effects of Focal Fat Reduction Drug at US Conference	11-02	MT
Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction	11-01	CI
Sirnaomics Buys US Unit's Shares for $1 Million	05/09/23	MT
Sirnaomics Completes Phase 1 Study Dosing of Cancer Medication	31/08/23	MT
Sirnaomics Narrows H1 Loss	31/08/23	MT
Sirnaomics Appoints Chief Strategy Officer	31/08/23	MT
Sirnaomics Ltd. Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors	31/08/23	CI
Sirnaomics Ltd. Announces Appointment of Chief Strategy Officer and Resignation of Joint Company Secretary	30/08/23	CI
Sirnaomics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Sirnaomics Names SVP for Preclinical and Clinical Development	28/07/23	MT
Sirnaomics Ltd. Appoints Francois Lebel as Senior Vice President for Preclinical and Clinical Development	27/07/23	CI
Sirnaomics to Purchase EDIRNA Shares In Exchange for Licensing	06/07/23	MT
Sirnaomics to Collaborate with EDIRNA for Edit-to-Cure Therapeutics Platform	06/07/23	MT
Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc	05/07/23	CI

Chart Sirnaomics Ltd.

Duration

Period

More charts

Company Profile

Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.004 USD

Average target price

9.231 USD

Spread / Average Target

+819.30%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SIRNAOMICS LTD.	-78.04%	83.34M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-0.29%	21.78B
GENMAB A/S	-9.28%	18.09B
WUXI APPTEC CO., LTD.	-41.70%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs